

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – September 9, 2015 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
 - A. July 8, 2015 DUR Minutes – Vote
 - B. July 8, 2015 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/FDA Safety Alerts – See Appendix B**
 - A. Medication Coverage Activity for July 2015
 - B. Pharmacy Help Desk Activity for July 2015
 - C. Medication Coverage Activity for August 2015
 - D. Pharmacy Help Desk Activity for August 2015
 - E. FDA Safety Alerts

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Hysingla® ER (Hydrocodone Bitartrate Extended-Release) – See Appendix C**
 - A. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Various Special Formulations: Sitavig® (Acyclovir Buccal Tablets), Rasuvo® (Methotrexate Injection), Otrexup™ (Methotrexate Injection), Onmel® (Itraconazole Oral Tablets), & Purixan® (Mercaptopurine Oral Suspension) – See Appendix D**
 - A. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Namzaric™ (Memantine Extended-Release/Donepezil) – See Appendix E**
 - A. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Irenka™ (Duloxetine) – See Appendix F**
 - A. College of Pharmacy Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

- 9. Action Item – Vote to Prior Authorize Corlanor® (Ivabradine) – See Appendix G**
A. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

- 10. 30-Day Notice to Prior Authorize Tykerb® (Lapatinib), Halaven® (Eribulin), Ixempra® (Ixabepilone), Kadcyła® (Ado-trastuzumab), Afinitor® (Everolimus), & Perjeta® (Pertuzumab) – See Appendix H**
A. Introduction
B. Utilization of Oncology Medications
C. Utilization of Breast Cancer Medications
D. Market News and Updates
E. Product Summaries
F. Recommendations
G. Utilization Details of Breast Cancer Medications

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

- 11. 30-Day Notice to Prior Authorize Orkambi™ (Lumacaftor/Ivacaftor) – See Appendix I**
A. Introduction
B. Orkambi™ (Lumacaftor/Ivacaftor) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 12. Action Item – Annual Review of Synagis® (Palivizumab) – See Appendix J**
A. Current Prior Authorization Criteria
B. Utilization of Palivizumab
C. Prior Authorization of Palivizumab
D. Referrals to Care Management Services
E. Market News and Updates
F. Guidance for Palivizumab Prophylaxis
G. Palivizumab Claims Analysis
H. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 13. Annual Review of Antihyperlipidemics and 30-Day Notice to Prior Authorize Epanova® (Omega-3-Carboxylic Acids), Praluent® (Alirocumab), and Repatha™ (Evolocumab) – See Appendix K**
A. Current Prior Authorization Criteria
B. Utilization of Antihyperlipidemics
C. Prior Authorization of Antihyperlipidemics
D. Market News and Updates
E. Epanova® (Omega-3-Carboxylic Acids) Product Summary
F. Praluent® (Alirocumab) Product Summary
G. Repatha™ (Evolocumab) Product Summary
H. Place in Therapy: PCSK9 Inhibitors
I. Cost Comparison: High-Intensity Statins and PCSK9 Inhibitors
J. College of Pharmacy Recommendations
K. Utilization Details of Statins and Zetia® (Ezetimibe)
L. Utilization Details of Lovaza® (Omega-3-Acid Ethyl Esters) and Vascepa® (Icosapent Ethyl)
M. Utilization Details of Juxtapid® (Lomitapide) and Kynamro® (Mipomersen)
N. Attachment A: Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)
O. Attachment B: Framingham Heart Study & Framingham Risk Score
P. Draft PCSK9 Inhibitor Prior Authorization Form

Items to be presented by Dr. Hsu, Dr. Muchmore, Chairman:

14. Annual Review of Anticoagulants and Platelet Aggregation Inhibitors and 30-Day Notice to Prior Authorize Savaysa™ (Edoxaban) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Anticoagulants and Platelet Aggregation Inhibitors
- C. Prior Authorization of Anticoagulants and Platelet Aggregation Inhibitors
- D. Oral Anticoagulants and Platelet Aggregation Inhibitors: Utilization Trends
- E. Market News and Updates
- F. Savaysa™ (Edoxaban) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Anticoagulants
- I. Utilization Details of Platelet Aggregation Inhibitors

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

15. FDA and DEA Updates – See Appendix M

Items to be presented by Dr. Muchmore, Chairman:

16. Adjournment